Product Detail
(19E/Z)-seco-[4-O-(2-Hydroxyethyl)] Rapamycin
Rapamycin Impurity
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Impurity
API Family
Rapamycin
Storage
Refer MSDS for complete information.
Hazard Information
Refer MSDS for complete information.
(19E/Z)-seco-[4-O-(2-Hydroxyethyl)] Rapamycin Product Information
(19E/Z)-seco-[4-O-(2-Hydroxyethyl)] Rapamycin is listed under Impurity. It is associated with Rapamycin and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-78909.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
(19E/Z)-seco-[4-O-(2-Hydroxyethyl)] Rapamycin
CAS No.
-
CAT No.
CS-T-78909
Molecular Formula
C₅₃H₈₃NO₁₄
Molecular Weight
958.22
Category
API Family
Storage Condition
Refer MSDS for complete information.
IUPAC Name
Everolimus EP Impurity B(EZ)
Hazard Compound
Refer MSDS for complete information.
Description
Overview
(19E/Z)-seco-[4-O-(2-Hydroxyethyl)] Rapamycin is a metabolite of the immunosuppressant macrolide SDZ RAD also known as Everolimus which is an analog of the parent drug Rapamycin.
Synonyms
(2S)-1-[2-Oxo-2-[(2R,3R,6S)-tetrahydro-2-hydroxy-6[(2S,3E,5E,7E,9S,11R,13R,14R,15E,17R,19E,21R)-14-hydroxy-22-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxo-3,5,7,15,19-docosapentaen-1-yl]-3-methyl-2H-pyran-2-yl]acetyl]-2-piperidinecarboxylic Acid,Everolimus Open Ring Alkene Impurity
Application Notes
(19E/Z)-seco-[4-O-(2-Hydroxyethyl)] Rapamycin is a metabolite of the immunosuppressant macrolide SDZ RAD also known as Everolimus which is an analog of the parent drug Rapamycin.
References
Vidal, C. et al.: J. Am. Soc. Mass Spec., 9, 1267 (1998); Kovarik, J. M., et al.: Clin. Pharmacol. Ther., 69, 48 (2001);
